Radius Health Company

Radius Health develops drug therapies for osteoporosis and women's health. The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life. Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging. Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.
Technology: Others
Industry: Longevity
Headquarters: Cambridge, Massachusetts, United States
Founded Date: 2003
Employees Number: 251-500
Funding Status: IPO
Total Funding: $688 000 000
Estimated Revenue: $10M to $50M
Last Funding Date: 2021-03-03
Last Funding Type: Post-IPO Debt

Visit Website
info@radiuspharm.com
https://www.twitter.com/radius_health
Register and Claim Ownership